What happened with BMY today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Bristol Myers Squibb brings medicines from research or licensing through development, manufacturing and sale worldwide. Product sales generate most revenue, with the United States its largest market and Eliquis and Opdivo its largest-selling medicines. Its direct buyers are mainly wholesalers, distributors and specialty pharmacies. McKesson, Cencora and Cardinal Health together account for most of its U.S. wholesale business.
What the company earns depends on both patient use and the prices healthcare payers will cover. Insurers and pharmacy benefit managers influence access through their covered-drug lists and negotiated rebates, while government programs require discounts and constrain prices. Eliquis is subject to a government-set price in Medicare, and the company has agreed to supply it free to Medicaid. Some medicines also have mandatory distribution restrictions: Camzyos can reach authorized patients only through certified pharmacies.
Patents and regulatory protections give its medicines periods of market exclusivity. Once that protection ends and lower-priced generics or biosimilars enter, sales can fall sharply. Replacing those sales depends on successfully developing and launching new medicines and gaining approval for additional uses of existing products, using both internal research and externally acquired or licensed drugs.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
As BMS works to replace declining legacy-drug sales with growth medicines, watch Roche, absent from this list, whose Tecentriq competes with Opdivo.
Pfizer and BMS jointly sell Eliquis and generally split its profits equally, so demand and pricing affect both, even as their cancer medicines compete. Watch Pfizer's Eliquis sales and news on generic entry; BMS estimates its earliest basic U.S. exclusivity loss in 2028, but that timing is not assured.
Merck competes with BMS for cancer-treatment sales through Keytruda versus Opdivo, but each also pays the other a share of sales: BMS on Reblozyl and Merck on Winrevair, as royalties. Watch Winrevair sales in Merck's results, since BMS receives 22% of its net sales.
AstraZeneca competes for cancer-treatment sales that BMS seeks through Opdivo: its Imfinzi is a rival in major cancer-treatment markets.
Johnson & Johnson competes for blood-cancer treatment sales with BMS: its Carvykti and multiple-myeloma medicines rival Abecma, Pomalyst and other BMS hematology treatments.
AbbVie competes for psoriasis-treatment sales with BMS's Sotyktu through Skyrizi and Humira, alongside broader overlap in immune-disease and cancer medicines. Watch sales of those two AbbVie drugs for a view of the competing treatments Sotyktu faces.
Gilead competes for blood-cancer cell-therapy sales with BMS's Breyanzi through Yescarta and Tecartus in markets where the treatments overlap.
Novartis competes with BMS in cancer and immune-disease medicines, including development of radioactive cancer treatments, or radiopharmaceuticals, and sales of psoriasis medicines. Its Cosentyx competes with Sotyktu, while its radiopharmaceutical development news helps track another area of BMS rivalry.
Amgen's Otezla competes directly with BMS's Sotyktu for patients using oral psoriasis medicines. Otezla sales are the Amgen revenue line to watch for competition facing Sotyktu, rather than Amgen's overall medicine sales.
Teva sells generic lenalidomide that competes with BMS's branded Revlimid, directly exposing BMS's drug sales to erosion from generic alternatives.
BeOne competes for cancer-immunotherapy sales with BMS through Tevimbra, a direct rival to Opdivo. Watch Tevimbra's sales and approvals rather than BeOne's leading blood-cancer drug BRUKINSA when assessing this pressure on Opdivo.
Regeneron's Libtayo competes with BMS's Opdivo, but Regeneron also pays to use patents associated with BMS to develop and sell Libtayo. Watch Libtayo sales and the end of the royalty obligation: the license requires payments of 2.5% of worldwide sales through December 31, 2026.
Takeda's top-selling Entyvio competes with BMS's Zeposia for ulcerative-colitis patients. Watch Entyvio sales with care: they also include treatment of Crohn's disease, so the full revenue line does not measure only its rivalry with Zeposia.
Bristol-Myers Squibb Co. earningsThis company
Bristol Myers Squibb’s older drugs face generic and pricing pressure, and this report will show whether its newer medicines can fill the gap while Eliquis and Opdivo hold up.
Read Growth Portfolio revenue against Legacy Portfolio revenue, then check Eliquis and Opdivo sales alongside U.S. net-price and rebate pressure. Continued growth in the newer portfolio with the two major brands holding up would show the transition is gaining ground; slowing growth or weakness in those brands would mean lost legacy sales and lower net prices are harder to replace.
Merck & Co., Inc. earningsMRK
Merck’s report will show Winrevair sales, on which Bristol Myers Squibb earns royalties, giving a direct read on one source of BMS income.
Watch Winrevair net sales and how they change: Bristol Myers Squibb receives 22% of those sales as royalties. Growing sales would lift that income stream; flat or falling sales would reduce its contribution. Merck’s overall results or cancer-drug sales alone cannot show whether Opdivo or Keytruda is gaining ground.
Pfizer Inc. earningsPFE
Pfizer’s report will show how jointly sold Eliquis is doing; the companies generally split its profits equally, so its sales and generic-entry signals matter to Bristol Myers Squibb too.
Watch the change in Pfizer’s reported Eliquis sales and any signs of generic entry. Continued sales growth would show demand supporting the shared business; weakening sales or generic entry would put pressure on the revenue and profits the companies share. Pfizer’s sales figure is not BMS’s standalone result.
